3D bioprinted cancer models: from basic biology to drug development
2022-11-25 16:50:30
SCI
13 November 2022
3D bioprinted cancer models: from basic biology to drug development
（Nature Reviews Cancer; IF: 69.800）
Lena Neufeld, Eilam Yeini, Sabina Pozzi, Ronit Satchi-Fainaro
CORRESPONDENCE TO: ronitsf@tauex.tau.ac.il
Abstract |
Effort
invested in the development of new drugs often fails to be translated
into meaningful clinical benefits for patients with cancer. The
development of more effective anticancer therapeutics and accurate
prediction of their clinical merit remain urgent unmet medical needs. As
solid cancers have complex and heterogeneous structures composed of
different cell types and extracellular matrices, three-dimensional (3D)
cancer models hold great potential for advancing our understanding of
cancer biology, which has been historically investigated in tumour cell
cultures on rigid plastic plates. Advanced 3D bioprinted cancer models
have the potential to revolutionize the way we discover therapeutic
targets, develop new drugs and personalize anticancer therapies in an
accurate, reproducible, clinically translatable and robust manner. These
ex vivo cancer models are already replacing existing in vitro systems
and could, in the future, diminish or even replace the use of animal
models. Therefore, profound understanding of the differences in
tumorigenesis between 2D, 3D and animal models of cancer is essential.
This Review presents the state of the art of 3D bioprinted cancer
modelling, focusing on the biological processes that underlie the
molecular mechanisms involved in cancer progression and treatment
response as well as on proteomic and genomic signatures.
